Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

PD 134308 MeSH Supplementary Concept Data 2025


MeSH Supplementary
PD 134308
Unique ID
C065599
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C065599
Entry Term(s)
4-((2-((3-(1H-indol-3-yl)-2-methyl-1-oxo-2-(((tricyclo(3.3.1.1)-dec-2-yloxy)carbonyl)amino)propyl)amino)-1-phenethyl)amino)-4-oxobutanoate N-methyl-D-glucamine
CI 988
CI-988
PD-134308
PD134308
Pharm Action
Antineoplastic Agents
Hormone Antagonists
Anti-Anxiety Agents
Registry Numbers
130404-91-0
Related Numbers
2637PDX9SI
Heading Mapped to
*Indoles
Meglumine / analogs & derivatives
Frequency
133
Note
selective cholecystokinin type B receptor antagonist; inhibits growth of LoVo, a human colon cancer cell line; structure given in first source
Source
Proc Natl Acad Sci USA 1990;87(17):6728
Date of Entry
1990/10/05
Revision Date
2018/11/20
PD 134308 Preferred
4-((2-((3-(1H-indol-3-yl)-2-methyl-1-oxo-2-(((tricyclo(3.3.1.1)-dec-2-yloxy)carbonyl)amino)propyl)amino)-1-phenethyl)amino)-4-oxobutanoate N-methyl-D-glucamine Broader
CI 988 Related
page delivered in 0.003s